In the field of Parkinson's disease (PD) therapeutics, the ultimate goal is to develop disease-modifying treatments that slow, prevent or reverse the underlying disease process. Validated biomarkers of disease progression would dramatically accelerate PD therapeutics research. Current progression biomarkers, however, are not optimal and are not fully validated.
The study has been initiated to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders for the development of early and accurate diagnostic tests, identification of novel treatment targets and to help understand the links between different pathologies and clinical symptoms.
The CSF Parkinson Perugia Cohort aimed at assessing the discriminating power of multiple cerebrospinal fluid (CSF) biomarkers for Parkinson's disease (PD) as well their ability in predictive cognitive decline. Several proteins were measured among those playing an important role in the disease pathogenesis: β-glucocerebrosidase and other lysosomal enzymes, together with α-synuc
Clinica NeurologicaOspedale S.Maria della Misericordia
Località S. Andrea delle Fratte - 06132 Perugia
P.I. Paolo Eusebi: Send mail to P.I. Paolo Eusebi
Research project funded by the Italian Ministry of Health RF-GR‐2013-02357757